BeOne Medicines Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
12,000
- Stock Symbol
-
06160
- Investments
-
13
- Share Price
-
$32.61
- (As of Thursday Closing)
BeOne Medicines General Information
Description
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Contact Information
Website
www.beonemedicines.comCorporate Office
- 30 Science Park Road
- Zhongguancun Life Science Park
- Beijing, 102206
- China
Corporate Office
- 30 Science Park Road
- Zhongguancun Life Science Park
- Beijing, 102206
- China
BeOne Medicines Stock Performance
As of 12-Nov-2026, BeOne Medicines’s stock price is $32.61. Its current market cap is $49.6B with 1.48B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $32.61 | $32.10 | $19.52 - $34.04 | $49.6B | 1.48B | 3.49M | $0.63 |
BeOne Medicines Financials Summary
As of 30-Sep-2026, BeOne Medicines has a trailing 12-month revenue of $6.61B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 39,768,049 | 31,963,441 | 18,868,380 | 17,112,455 |
| Revenue | 6,606,494 | 5,343,033 | 3,810,241 | 2,458,779 |
| EBITDA | 1,335,761 | 546,269 | (409,075) | (812,170) |
| Net Income | 915,572 | 286,933 | (644,786) | (881,708) |
| Total Assets | 9,875,925 | 8,188,573 | 5,920,910 | 5,805,275 |
| Total Debt | 1,148,766 | 1,092,844 | 1,079,866 | 930,185 |
BeOne Medicines Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BeOne Medicines Comparisons
Industry
Financing
Details
BeOne Medicines Competitors (49)
One of BeOne Medicines’s 49 competitors is Syndax, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Syndax | Formerly VC-backed | Waltham, MA | ||||
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| Polaris Group (Drug Discovery) | Formerly PE-Backed | Chengdu, China | ||||
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| Noxopharm | Corporation | Castle Hill, Australia |
BeOne Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BeOne Medicines Patents
BeOne Medicines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025146131-A1 | Anti-fgfr2b antibodies, conjugates and methods of use | Inactive | 05-Jan-2024 | ||
| WO-2025124456-A1 | Antibody drug conjugate platforms | Inactive | 13-Dec-2023 | ||
| WO-2025011660-A1 | Two-stage multi-task learning-based method and system for automated lesion response assessment | Inactive | 12-Jul-2023 | ||
| WO-2025002368-A1 | Bioactive conjugates, preparation method and use thereof | Inactive | 29-Jun-2023 | ||
| WO-2025002370-A1 | Bioactive conjugates, preparation method and use thereof | Inactive | 29-Jun-2023 | A61K47/68031 |
BeOne Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BeOne Medicines Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BeOne Medicines Investments & Acquisitions (13)
BeOne Medicines’s most recent deal was a Later Stage VC with Terremoto Biosciences for . The deal was made on 15-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Terremoto Biosciences | 15-Apr-2026 | Later Stage VC | Drug Delivery | ||
| Recorna | 28-Jun-2024 | Early Stage VC | Drug Discovery | ||
| Ensem (Global Rights To Experimental Cancer Therapy) | 21-Nov-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Duo Oncology | 11-Aug-2023 | Seed Round | Drug Discovery | ||
| Strand Therapeutics | 28-Nov-2022 | Later Stage VC | Drug Discovery |
BeOne Medicines ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
21.46 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
BeOne Medicines Exits (2)
BeOne Medicines’s most recent exit was on 02-Nov-2021 from Shoreline Biosciences. The exit was categorized as with 18 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Shoreline Biosciences | 02-Nov-2021 | Completed |
|
||
| Cypherpunk Technologies | 24-Jan-2020 | PIPE | Completed |
|
BeOne Medicines FAQs
-
When was BeOne Medicines founded?
BeOne Medicines was founded in 2010.
-
Where is BeOne Medicines headquartered?
BeOne Medicines is headquartered in Beijing, China.
-
What is the size of BeOne Medicines?
BeOne Medicines has 12,000 total employees.
-
What industry is BeOne Medicines in?
BeOne Medicines’s primary industry is Drug Discovery.
-
Is BeOne Medicines a private or public company?
BeOne Medicines is a Public company.
-
What is BeOne Medicines’s stock symbol?
The ticker symbol for BeOne Medicines is 06160.
-
What is the current stock price of BeOne Medicines?
As of 12-Nov-2026 the stock price of BeOne Medicines is $32.61.
-
What is the current market cap of BeOne Medicines?
The current market capitalization of BeOne Medicines is $49.6B.
-
What is BeOne Medicines’s current revenue?
The trailing twelve month revenue for BeOne Medicines is $6.61B.
-
Who are BeOne Medicines’s competitors?
Syndax, Celldex, Polaris Group (Drug Discovery), Alphamab Oncology, and Noxopharm are some of the 49 competitors of BeOne Medicines.
-
What is BeOne Medicines’s annual earnings per share (EPS)?
BeOne Medicines’s EPS for 12 months was $0.63.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
